Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00133822 · ClinicalTrials.gov registry record · Phase 1

Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial

A Phase 1 study of Post-Traumatic Stress Disorders, sponsored by Emory University.

Completed
Registry status
Phase 1
Development phase
65
Enrollment target
3
Study locations

NCT00133822 is a Phase 1 study of Post-Traumatic Stress Disorders that has completed, run by Emory University. The registered enrollment target is 65 participants, below the 74-participant average among 5 other Post-Traumatic Stress Disorders trials with a reported enrollment target (12% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00133822, a Phase 1 study of Post-Traumatic Stress Disorders, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 1
Development phase
65 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine whether the administration of risperidone is effective in the treatment of selective serotonin reuptake inhibitor (SSRI)-resistant post-traumatic stress disorder (PTSD) in civilians.

Interventions

  • DRUG Sertraline and Risperidone

Study Locations (3)

Georgia

  • Emory University School of Medicine - Atlanta

North Carolina

  • Duke University Medical Center South - Durham

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2004-04
Est. Completion 2006-09
Phase Phase 1

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT00133822

The ClinicalTrials.gov registry entry for NCT00133822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 5 other Post-Traumatic Stress Disorders trials with a reported enrollment target (12% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post-Traumatic Stress Disorders appearing as the primary indexed condition, and to 1 intervention - of which Sertraline and Risperidone is the first listed.

NCT00133822 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, North Carolina, South Carolina.

Frequently Asked Questions

What is clinical trial NCT00133822 about?

NCT00133822 is a clinical study titled "Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial". The purpose of this study is to determine whether the administration of risperidone is effective in the treatment of selective serotonin reuptake inhibitor (SSRI)-resistant post-traumatic stress disorder (PTSD) in civilians.

What is the current status of trial NCT00133822?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2004-04. Estimated completion is 2006-09.

What conditions does trial NCT00133822 study?

This clinical trial studies the following conditions: Post-Traumatic Stress Disorders.

What interventions are being tested in trial NCT00133822?

The interventions under investigation include: Sertraline and Risperidone (DRUG).

Who is sponsoring clinical trial NCT00133822?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00133822 being conducted?

This trial has 3 study locations across Georgia, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Traumatic Stress Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.